Xeris Biopharma Holdings, Inc.
Financials
Valuation Metrics
Xeris Biopharma Holdings, Inc.'s Market Cap is $1.49B. At end of 2025 it was $1.30B. Ranked #2224 of 3,121 in US market (top 71%), #880 of 1,463 on NASDAQ (top 60%), #164 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.49B | US#2,224/3,121 Sec#164/266 |
| Revenue | $335M | US#2,414/3,121 Sec#90/266 |
| Net Income | $-17M | US—/3,121 Sec—/266 |
| Total Assets | $412M | US#2,837/3,121 Sec#184/266 |
| Net Assets | $-10M | US#2,927/3,121 Sec#243/266 |
| Employees | 435 | US#2,317/3,121 Sec#86/266 |
| Value | ||
| P/S | 4.44x | US#2,187/3,121 Sec#69/266 |
| EV/EBITDA | 100.86x | US#2,437/3,121 Sec#80/266 |
| FCF Yield | 3.72% | US#1,687/3,121 Sec#52/266 |
| Profitability | ||
| ROA | -4.17% | US#2,491/3,121 Sec#83/266 |
| Op. Margin | 10.91% | US#1,523/3,121 Sec#60/266 |
| Revenue Growth | 36.33% | US#340/3,121 Sec#54/266 |
| Financial Health | ||
| Total Debt | $289M | US#2,115/3,121 Sec#80/266 |
| FCF | $55M | US#1,951/3,121 Sec#68/266 |
| Cash | $122M | US#2,091/3,121 Sec#155/266 |
| Current Ratio | 1.45x | US#1,724/3,121 Sec#240/266 |
| Net Debt/EBITDA | 10.22x | US#2,361/3,121 Sec#83/266 |
| Performance | ||
| 1Y Return | 6.39% | US#1,599/3,121 Sec#176/266 |
| 1M Return | -7.80% | US#2,170/3,121 Sec#163/266 |
| From 52W High | -19.05% | US#1,444/3,121 Sec#104/266 |
| 1Y MDD | -46.57% | US#2,309/3,121 Sec#168/266 |
| Trading | ||
| Volume | 2,312,540 shares | US#739/3,121 Sec#74/266 |
| Trading Value | $19M | US#1,931/3,121 Sec#150/266 |
| Per Share | ||
| EPS | $-0.09 | US—/3,121 Sec—/266 |
| BPS | $-0.05 | US—/3,121 Sec—/266 |
Company Info
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.